OpenNashEarnings

Life Sciences · Nasdaq: IDXX

IDEXX Laboratories earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 1 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

IDEXX placed over 1,900 inVue Dx analyzers in the quarter and bought AI clinical assistant CoVet, extending its diagnostics-plus-software push in veterinary practices.

IDEXX's growth this quarter was driven by volume, led by the inVue Dx analyzer, which had over 1,900 placements and brings the installed base to nearly 11,000 instruments. The premium instrument base grew 11% globally, and VetLab consumables use rose with new product launches. IDEXX Cancer Dx became a multi-cancer panel. International regions grew faster than the U.S., and imaging installations were strong, led by ImageVue DR50 Plus.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$1.2B+9.9% y/yQ3 2026
Q4 2024: $954.3M (worked out from the annual figure)Q4 ’24$954.3MQ1 2025: $998.4MQ1 ’25$998.4MQ2 2025: $1.1BQ2 ’25$1.1BQ3 2025: $1.1BQ3 ’25$1.1BQ4 2025: $1.1B (worked out from the annual figure)Q4 ’25$1.1BQ1 2026: $1.1BQ1 ’26$1.1BQ2 2026: $1.2BQ2 ’26$1.2BQ3 2026: $1.2BQ3 ’26$1.2B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$954.3M *
Q1 2025$998.4M
Q2 2025$1.1B
Q3 2025$1.1B
Q4 2025$1.1B *
Q1 2026$1.1B
Q2 2026$1.2B
Q3 2026$1.2B
Diluted EPS (GAAP)$4.01+17.9% y/yQ3 2026
Q1 2025: $2.96Q1 ’25$2.96Q2 2025: $3.63Q2 ’25$3.63Q3 2025: $3.40Q3 ’25$3.40Q1 2026: $3.47Q1 ’26$3.47Q2 2026: $4.27Q2 ’26$4.27Q3 2026: $4.01Q3 ’26$4.01
Data
Q1 2025$2.96
Q2 2025$3.63
Q3 2025$3.40
Q1 2026$3.47
Q2 2026$4.27
Q3 2026$4.01

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin33.1%+1.0 pts y/yQ3 2026
Q4 2024: 27.4%Q4 ’2427.4%Q1 2025: 31.7%Q1 ’2531.7%Q2 2025: 33.6%Q2 ’2533.6%Q3 2025: 32.1%Q3 ’2532.1%Q4 2025: 28.9%Q4 ’2528.9%Q1 2026: 31.8%Q1 ’2631.8%Q2 2026: 35.0%Q2 ’2635.0%Q3 2026: 33.1%Q3 ’2633.1%
Data
Q4 202427.4%
Q1 202531.7%
Q2 202533.6%
Q3 202532.1%
Q4 202528.9%
Q1 202631.8%
Q2 202635.0%
Q3 202633.1%
Free cash flow$420.8M+13.4% y/yQ3 2026
Q4 2024: $232.8MQ4 ’24$232.8MQ1 2025: $207.9MQ1 ’25$207.9MQ2 2025: $151.6MQ2 ’25$151.6MQ3 2025: $371.2MQ3 ’25$371.2MQ4 2025: $326.3MQ4 ’25$326.3MQ1 2026: $234.3MQ1 ’26$234.3MQ2 2026: $322.5MQ2 ’26$322.5MQ3 2026: $420.8MQ3 ’26$420.8M
Data
Q4 2024$232.8M
Q1 2025$207.9M
Q2 2025$151.6M
Q3 2025$371.2M
Q4 2025$326.3M
Q1 2026$234.3M
Q2 2026$322.5M
Q3 2026$420.8M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$954.3Md$998.4M$1.1B$1.1B$1.1Bd$1.1B$1.2B$1.2B
Gross margin59.8%62.4%62.6%61.8%60.3%63.4%64.0%62.9%
Operating income$261.7Md$316.5M$373.0M$354.8M$315.6Md$362.6M$425.6M$402.3M
Operating margin27.4%31.7%33.6%32.1%28.9%31.8%35.0%33.1%
Net income$216.1Md$242.7M$294.0M$274.6M$248.2Md$278.4M$338.4M$317.1M
Diluted EPS—$2.96$3.63$3.40—$3.47$4.27$4.01
Operating cash flow$262.0Md$238.0M$185.7Md$402.3Md$355.8Md$266.2M$347.2Md$449.7Md
Capital expenditure$29.3Md$30.0M$34.1Md$31.1Md$29.4Md$32.0M$24.6Md$28.9Md
Free cash flow$232.8M$207.9M$151.6M$371.2M$326.3M$234.3M$322.5M$420.8M
R&D expense$57.7Md$59.1M$61.9M$63.4M$66.8Md$65.8M$65.4M$68.8M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings